Denali Advisors LLC Takes $228,000 Position in Applied Therapeutics, Inc. (NASDAQ:APLT)

Denali Advisors LLC bought a new stake in Applied Therapeutics, Inc. (NASDAQ:APLT) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 33,600 shares of the company’s stock, valued at approximately $228,000.

A number of other institutional investors have also modified their holdings of APLT. Vontobel Holding Ltd. bought a new position in Applied Therapeutics in the 4th quarter worth about $34,000. Jump Financial LLC bought a new position in Applied Therapeutics in the 4th quarter worth about $81,000. Citigroup Inc. bought a new position in Applied Therapeutics in the 3rd quarter worth about $164,000. Worth Venture Partners LLC bought a new position in shares of Applied Therapeutics in the third quarter valued at approximately $483,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Applied Therapeutics in the third quarter valued at approximately $1,139,000. Institutional investors and hedge funds own 98.31% of the company’s stock.

Insider Transactions at Applied Therapeutics

In other Applied Therapeutics news, major shareholder Real Estate Equitie Alexandria sold 150,000 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $4.21, for a total value of $631,500.00. Following the transaction, the insider now directly owns 6,005,077 shares in the company, valued at $25,281,374.17. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO Leslie D. Funtleyder sold 16,980 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $4.32, for a total transaction of $73,353.60. Following the transaction, the chief financial officer now directly owns 291,441 shares in the company, valued at $1,259,025.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Real Estate Equitie Alexandria sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.21, for a total transaction of $631,500.00. Following the transaction, the insider now owns 6,005,077 shares in the company, valued at $25,281,374.17. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 250,778 shares of company stock worth $1,066,861. 8.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

APLT has been the subject of a number of research reports. UBS Group raised their target price on shares of Applied Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Royal Bank of Canada reissued an “outperform” rating and set a $12.00 target price on shares of Applied Therapeutics in a research note on Thursday, April 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $11.00.

Applied Therapeutics Stock Performance

APLT traded up $0.03 during trading on Wednesday, hitting $4.38. The stock had a trading volume of 556,330 shares, compared to its average volume of 1,599,356. Applied Therapeutics, Inc. has a 12 month low of $1.18 and a 12 month high of $9.39. The company has a 50 day simple moving average of $4.50 and a 200-day simple moving average of $4.50.

Applied Therapeutics (NASDAQ:APLT) last announced its earnings results on Thursday, May 9th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $10.00 million. As a group, analysts expect that Applied Therapeutics, Inc. will post -0.59 earnings per share for the current year.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.